Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC

Expert Opinion on Biological Therapy

Volumn 12, Issue SUPPL. 1, 2012, Pages

  Szpechcinski, Adam ^a   Chorostowska Wynimko, Joanna ^a   Kupis, Wlodzimierz ^a   Maszkowska Kopij, Krystyna ^a   Dancewicz, MacIej ^b   Kowalewski, Janusz ^b   Orlowski, Tadeusz ^a  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Free circulating DNA; Non small cell lung cancer; Plasma; Real time PCR; Resection; Trauma

Indexed keywords

DNA;

AGED; BLOOD; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIP SURGERY; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PATIENT MONITORING; QUANTITATIVE ANALYSIS; THERAPY EFFECT;

BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DNA; DNA PRIMERS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84861448570     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.668519     Document Type: Conference Paper

References (13)

1. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids-a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007; 581: 795-9 (Pubitemid 46282711)
2. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007; 1775: 181-232 (Pubitemid 44911084)
3. Chorostowska-Wynimko J, Szpechcinski A. The impact of genetic markers on the diagnosis of lung cancer: a current perspective. J Thorac Oncol 2007; 2: 1044-51 (Pubitemid 350059582)
4. Szpechcinski A, Struniawski R, Zaleska J, et al. Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients. J Physiol Pharmacol 2008; 59: 675-81
5. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001; 61: 4675-8 (Pubitemid 32691874)
6. Paci M, Maramotti S, Bellesia E, et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 2009; 64: 92-7
7. Ludovini V, Pistola L, Gregorc V, et al. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the Perugia multidisciplinary team for thoracic oncology. J Thorac Oncol 2008; 3: 365-73 (Pubitemid 351489476)
8. Tamkovich SN, Bryzgunova OE, Rykova EY, et al. Circulating nucleic acids in blood of healthy male and female donors. Clin Chem 2005; 51: 1317-19 (Pubitemid 43079438)
9. Jylhävä J, Kotipelto T, Raitala A, et al. Aging is associated with quantitative and qualitative changes in circulating cell-free DNA: the Vitality 90+ study. Mech Ageing Dev 2011; 132: 20-6
10. Sozzi G, Conte D, Leon M, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003; 21: 3902-8 (Pubitemid 46606202)
11. Yoon KA, Park S, Lee SH, et al. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn 2009; 11: 182-5
12. Lo YM, Rainer TH, Chan LY, et al. Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000; 46: 319-23 (Pubitemid 30152256)
13. Lam NY, Rainer TH, Chan LY, et al. Time course of early and late changes in plasma DNA in trauma patients. Clin Chem 2003; 49: 1286-91 (Pubitemid 36900614)